Free tool
FAERS Monitor: Qbrelis
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208401 or its brand name (Qbrelis, Lisinopril). Reports on generic versions are filed under their own applications.
Reports
297,814
Serious
179,948
60% of reports
Hospitalization
93,925
Death reported
24,314
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue19,506
- nausea18,031
- drug ineffective17,342
- diarrhoea17,024
- dyspnoea13,566
- pain13,270
- dizziness13,181
- headache12,634
- off label use10,862
- vomiting10,679
- asthenia10,625
- arthralgia9,421
- acute kidney injury9,401
- chronic kidney disease9,006
- fall8,850
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2,862 |
| 2005 | 3,787 |
| 2006 | 4,148 |
| 2007 | 4,265 |
| 2008 | 5,347 |
| 2009 | 7,302 |
| 2010 | 10,347 |
| 2011 | 10,674 |
| 2012 | 12,559 |
| 2013 | 12,112 |
| 2014 | 17,292 |
| 2015 | 21,708 |
| 2016 | 22,448 |
| 2017 | 21,228 |
| 2018 | 23,130 |
| 2019 | 22,371 |
| 2020 | 17,828 |
| 2021 | 15,520 |
| 2022 | 15,022 |
| 2023 | 13,033 |
| 2024 | 12,476 |
| 2025 | 13,426 |
| 2026 | 8,929 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,756,345 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 9,006 | 9.4 | 9.2 | 59,500 |
| acute kidney injurySignal | 9,401 | 4.6 | 4.5 | 24,674 |
| astheniaSignal | 10,625 | 2.0 | 2.0 | 5,450 |
| fall | 8,850 | 1.9 | 1.9 | 3,743 |
| dizziness | 13,181 | 1.9 | 1.9 | 5,507 |
| diarrhoea | 17,024 | 1.9 | 1.9 | 7,116 |
| fatigue | 19,506 | 1.8 | 1.8 | 6,874 |
| dyspnoea | 13,566 | 1.7 | 1.7 | 4,006 |
| nausea | 18,031 | 1.6 | 1.6 | 4,380 |
| vomiting | 10,679 | 1.6 | 1.6 | 2,520 |
| arthralgia | 9,421 | 1.6 | 1.6 | 2,194 |
| pain | 13,270 | 1.5 | 1.5 | 2,511 |
| headache | 12,634 | 1.4 | 1.4 | 1,662 |
| drug ineffective | 17,342 | 0.9 | 0.9 | 101 |
| off label use | 10,862 | 0.9 | 0.9 | 201 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.